TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31985080
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 µg/kg) administered at the end of surgery
Study: 31985080
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 µg/kg) administered 10 to 15 minutes before the end of surgery
Study: 31162894
Drug: Galavit in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galavit in combination with standard therapy
Study: 20823089
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin infusion before exchange transfusion
Study: 17314110
Drug: Lp-PLA(2) levels
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp-PLA(2) levels in ACS patients (median 305 ng/mL in FRISC II, 373 ng/mL in GUSTO IV)
Study: 17314110
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (median Lp-PLA(2) 254 ng/mL)
Study: 15205386
Drug: Tolbutamide, Ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide, Ibuprofen, Fluvastatin
Study: 15205386
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro drug-drug interaction potential
Study: 11535487
Drug: Defibrillation as
Normalized name: sotalol
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Defibrillation as the primary treatment for VF
Study: 31593002
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (5 daily sessions, 500 pulses per session at 5 Hz)
Study: 31593002
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS (5 daily sessions)
Study: 31593002
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (4 weekly sessions, open-label continuous trial)
Study: 31593002
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS (4 weekly sessions, open-label continuous trial)
Study: 26983904
Drug: Child-Centered Therapy
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-Centered Therapy (CCT)
Study: 8866039
Drug: Fast-dissolving ketorolac
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fast-dissolving ketorolac tablet
Study: 8866039
Drug: Medium-1 dissolving
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-1 dissolving ketorolac tablet
Study: 8866039
Drug: Medium-2 dissolving
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-2 dissolving ketorolac tablet
Study: 8866039
Drug: Slow-dissolving ketorolac
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-dissolving ketorolac tablet
Study: 19920413
Drug: Continuous preperitoneal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous preperitoneal wound infusion (CPWI) of 0.2% ropivacaine at 10 mL/hr for 48 hrs
Study: 19920413
Drug: Conventional parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional parenteral analgesia (intravenously administered morphine via patient‐controlled analgesia and acetaminophen) without parietal analgesia
Study: 15700916
Drug: Cessation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation treatment for smokers with past major depressive disorder
Study: 8510514
Drug: 23 g
Normalized name: PEG-23 GLYCERYL DISTEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 g parboiled white rice (20 g available carbohydrate)
Study: 8510514
Drug: 46 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 46 g parboiled white rice (40 g available carbohydrate)
Study: 8510514
Drug: 69 g
Normalized name: DIMETHICONE 3.69 g in 55 g CUTANEOUS CREAM [GOLDKIWI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 69 g parboiled white rice (60 g available carbohydrate)
Study: 8510514
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for glucosuria after 20 g carbohydrate
Study: 8510514
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for glucosuria after 40 g carbohydrate
Study: 8510514
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for glucosuria after 60 g carbohydrate
Study: 29447382
Drug: Group acupuncture
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group acupuncture (20 treatments over 10 weeks, 900 minutes total)
Study: 17712352
Drug: LY544344 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY544344 16 mg b.i.d.
Study: 17712352
Drug: LY544344 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY544344 8 mg b.i.d.
Study: 16671425
Drug: Indomethacin (IND)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IND) 100 mg transrectally and 6 mg/kg/day for 14 days
Study: 16671425
Drug: Indomethacin (IND)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IND) 6 mg/kg/day for 14 days
Study: 1963191
Drug: Active antihypertensive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antihypertensive treatment
Study: 9373658
Drug: Mefloquine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (15 mg base/kg)
Study: 8385430
Drug: MK-886 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-886 (500 mg and 250 mg)
Study: 27100959
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg three times a day for 1 year)
Study: 24823461
Drug: GH treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment: 33 or 67 μg/kg · d
Study: 18661687
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of HBB plus 2.5 microg of intrathecal sufentanil
Study: 18661687
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of HBB plus 5 microg of intrathecal sufentanil
Study: 18661687
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of HBB
Study: 18661687
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of HBB plus 5 microg of subcutaneous sufentanil
Study: 15968954
Drug: 40 microg
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microg intramuscular hepatitis B vaccine (group 1)
Study: 15968954
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg intradermal hepatitis B vaccine (group 2)
Study: 10231930
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) and serum prostate specific antigen (PSA) > 4.0 ng/ml
Study: 10231930
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) alone
Study: 1423942
Drug: Candoxatril 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 25 mg every 12 hours (group 1)
Study: 1423942
Drug: Candoxatril 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 100 mg every 12 hours (group 2)
Study: 26385030
Drug: Intravenous loop
Normalized name: LOOP OSTOMY ROD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous loop diuretics
Study: 27054824
Drug: Therapist-reported alliance
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-reported alliance in alliance-focused therapy
Study: 24491134
Drug: Movement as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement as Medicine for Type 2 Diabetes intervention
Study: 20039105
Drug: Pramipexole slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole slow-release formulations
Study: 20039105
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) formulation
Study: 17681969
Drug: sublingual oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual oxybutynin 5 mg every 8 h during the 24 h after surgery
Study: 17681969
Drug: sublingual oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual oxybutynin 5 mg
Study: 16185789
Drug: Overall preference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall preference after chemotherapy
Study: 10364025
Drug: Rectal isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal isobaric distension (tonic mode)
Study: 10364025
Drug: Rectal isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal isobaric distension (phasic mode)
Study: 2040934
Drug: Ibuprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (300 mg for the first month, 400 mg for the second month, 600 mg for the third month)
Study: 2040934
Drug: Ibuprofen (13.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (13.4 +/- 4.1 mg/kg)
Study: 7075655
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg and codeine phosphate 60 mg
Study: 3737440
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 60 mg
Study: 10511349
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg
Study: 30928823
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin calcium (4 mg/day)
Study: 27625743
Drug: Pharmacist-provided telephonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-provided telephonic medication therapy management (MTM)
Study: 25046167
Drug: Ponesimod 10-100
Normalized name: ponesimod 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod 10-100 mg
Study: 25046167
Drug: Ponesimod 60-80
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ponesimod 60-80 mg
Study: 17925136
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment combined with supervised exercises
Study: 9013370
Drug: Anabolic steroids
Normalized name: ANABOLIC STEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic steroids
Study: 2692687
Drug: Bendrofluazide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide plus long-acting propranolol (80 mg)
Study: 2692687
Drug: Bendrofluazide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide plus long-acting propranolol (160 mg)
Study: 25818060
Drug: Opioid agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid agonist therapy
Study: 25818060
Drug: No agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: No agonist therapy
Study: 25818060
Drug: Engagement in
Normalized name: Bispecific t-cell engager antibody regn4018
DrugBank: Ubamatamab (DB18875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engagement in agonist therapy
Study: 23633201
Drug: Oral mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mixed meal test (MMT)
Study: 22029232
Drug: Clindamycin hydrochloride
Normalized name: Clindamycin Hydrochloride
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin hydrochloride (test formulation)
Study: 29229430
Drug: Proactive Self-Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive Self-Management Program for Effects of Cancer Treatment (PROSPECT), 8 weeks duration
Study: 22728166
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins (vitamins E 1200 IU and C 1000 mg)
Study: 16908620
Drug: Erythropoietin concentrations
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin concentrations > or = 500 mU/mL
Study: 16908620
Drug: Erythropoietin concentrations
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin concentrations < 500 mU/mL
Study: 15645891
Drug: Crest Whitestrips
Normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crest Whitestrips Supreme (14% hydrogen peroxide, 100 mg on maxillary strip), used twice daily for 30 minutes for 6 weeks
Study: 15645891
Drug: Crest Whitestrips
Normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crest Whitestrips Supreme (14% hydrogen peroxide, 100 mg on maxillary strip), used twice daily for 30 minutes for 3 weeks
Study: 9354312
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg orally)
Study: 8438847
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg in the morning for 2 weeks, followed by 20 mg for an additional 4 weeks if unhealed.
Study: 8438847
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at night for 2 weeks, followed by open treatment with omeprazole if unhealed.
Study: 8438847
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg treatment.
Study: 3320390
Drug: Intracoronary urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary urokinase (UK) therapy
Study: 30905643
Drug: 6.0 mg
Normalized name: Dimethicone 6.0 mg in 30 mL TOPICAL CREAM [Clapiel Revital Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 mg faricimab
Study: 30905643
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg faricimab
Study: 30905643
Drug: Faricimab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab (both doses)
Study: 20660037
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 mg iv) alone and in combination with breakfast (550 kcal)
Study: 20660037
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 mg iv) in combination with breakfast (550 kcal)
Study: 20660037
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline) alone and in combination with breakfast
Study: 12190903
Drug: Labial infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labial infiltration of 1.0 mL
Study: 12190903
Drug: Lingual infiltration
Normalized name: Nitroglycerin Lingual Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingual infiltration of 1.0 mL
Study: 12190903
Drug: Combined labial
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined labial and lingual infiltration (0.5 mL each)
Study: 12190903
Drug: Intraligamentary injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamentary injection (118 mL, 2% lidocaine with 1:80,000 adrenaline)
Study: 30287714
Drug: Intraligamentary injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamentary injection
Study: 22000449
Drug: Buccal infiltrations
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltrations
Study: 12190903
Drug: Intraligamentary injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamentary injections
Study: 9706923
Drug: Betamethasone 12
Normalized name: Betamethasone 120 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 12 mg i.m. 30 min before surgery (Group B)
Study: 7843443
Drug: Short GnRH
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short GnRH agonist protocol (900 micrograms/d buserelin acetate intranasally from day 1, followed by hMG from day 3)
Study: 7843443
Drug: hMG administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hMG administration from day 3 of the menstrual cycle (control group)
Study: 2132417
Drug: 100 W
Normalized name: Iron 100 with Vitamin C Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 W exercise treatment
Study: 2132417
Drug: 175 W
Normalized name: pediatric multivitamin no.175 with fluoride 1 mg fluoride ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 W exercise treatment
Study: 927305
Drug: Drug B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug B (Dihydrocodeine, Remedacen)
Study: 927305
Drug: Drug A
Normalized name: Drug additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A (Codeine, Phenyltoloxamine)
Study: 25144134
Drug: Lower body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower body strength (LBS) group performing resistance and power-oriented training (full squat, split squat, CMJ loaded, CMJ) twice per week in addition to in-water training
Study: 22036640
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ultrasound-guided aspiration and C-reactive protein
Study: 19255036
Drug: Head cooling
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head cooling for 72 hours starting within 6 hours of birth, rectal temperature maintained at 34.5 degrees C +/- 0.5 degrees C
Study: 17605489
Drug: Orthosystem implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthosystem implant installation
Study: 9552948
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (current medical treatment)
Study: 28118402
Drug: Direct Renin
Normalized name: DIRECT RENIN INHIBITOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Renin Inhibition (DRI; aliskiren 300 mg/day)
Study: 28118402
Drug: Angiotensin Converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin Converting Enzyme Inhibition (ACEi; ramipril 10 mg/day)
Study: 17339133
Drug: Contrast temperature
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast temperature water therapy
Study: 15274095
Drug: BDP-CFC aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP-CFC aerosol (>or= 500 mcg/day) via nasal inhalation
Study: 15274095
Drug: 200 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg/day of aqueous intranasal beclomethasone plus oral inhalation of BDP-CFC (>or= 500 mcg/day)
Study: 8088931
Drug: doxofylline 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxofylline 800 mg b.i.d.
Study: 8088931
Drug: theophylline slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: theophylline slow-release 400 mg b.i.d.
Study: 8088931
Drug: bamifylline 1200
Normalized name: bamifylline
DrugBank: Bamifylline (DB13203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bamifylline 1200 mg b.i.d.
Study: 3318434
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of nabumetone as a single bedtime dose
Study: 3318434
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of aspirin in four divided doses
Study: 26658441
Drug: Radiosurgery (22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiosurgery (22 Gy margin dose, follow-up 86 months)
Study: 24631386
Drug: Yacon flour
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon flour (0.14 g of fructooligosaccharides/kg of body weight daily) for 18 weeks
Study: 23035743
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea catechin (GTC) supplementation (630.9 mg GTC daily, n=26)
Study: 7533461
Drug: Finasteride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (10 mg/d)
Study: 2529375
Drug: Cilazapril 5
Normalized name: cilazapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5 mg orally
Study: 28186540
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous erythropoiesis receptor activator (CERA; monthly dose 30–75 µg)
Study: 28186540
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous erythropoiesis receptor activator (CERA)
Study: 23247045
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with steroids plus pentostatin, mycophenolate mofetil, etanercept, or denileukin diftitox
Study: 21839033
Drug: Topical cosmetic
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cosmetic product containing various active ingredients of botanical origin
Study: 11780330
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg to 25 mg t.i.d.)
Study: 793705
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only
Study: 8515495
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with high-dose chemotherapy (cyclophosphamide 1875 mg/m2, cisplatin 55 mg/m2, carmustine 600 mg/m2) followed by autologous bone marrow reinfusion.
Study: 8515495
Drug: Observation until
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation until relapse followed by the same high-dose chemotherapy and autologous bone marrow reinfusion.
Study: 8515495
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (immediate treatment and observation)
Study: 27579536
Drug: Tivantinib (MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (MET inhibitor)
Study: 20698216
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate 75 mg twice daily (n = 16)
Study: 20698216
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg once daily (n = 17)